scFv-Transferrin Fusion Protein for Intracellular Antibody Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of transcytosis, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis, with environmentally sensitive linkers for controlled release within target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used to bind target proteins, then effector functions and half-life are improved, but penetration through biological barriers and cellular uptake are reduced
Solution Approach 1:
The antibody is segmented into its essential functional component (scFv) that retains antigen-binding capability while removing the Fc region. This segmentation reduces molecular size from 150 kDa to 25-30 kDa, enabling better penetration through biological barriers while maintaining target binding efficacy
Solution Approach 2:
The Fc region is extracted from the complete antibody structure, retaining only the scFv portion that is necessary for antigen binding. This extraction eliminates the bulk mass that hinders barrier penetration while preserving the therapeutic function of target recognition and binding
2Length of moving object
If scFv is used to reduce molecular size and improve penetration, then transcytosis and cellular uptake are enhanced, but effector functions and half-life are reduced
Solution Approach 1:
Transferrin is introduced as an intermediary carrier protein that mediates the delivery of scFv across biological barriers. The transferrin-scFv conjugate utilizes the transferrin receptor-mediated endocytosis pathway, enhancing cellular uptake and transcytosis while the transferrin portion contributes to prolonged circulation half-life
Solution Approach 2:
The therapeutic agent is constructed as a composite system combining scFv (for target binding) with transferrin (for barrier penetration and extended half-life). This composite structure integrates the advantages of both components: the small size and specificity of scFv with the barrier-crossing and pharmacokinetic benefits of transferrin
3Area of stationary object
If antibodies are designed to cross the blood-brain barrier, then delivery to brain tissues is improved, but off-target effects and reduced specificity may occur
Solution Approach 1:
The scFv component provides localized specificity by maintaining precise antigen-binding capability only at the target site. The transferrin-mediated delivery system concentrates the scFv specifically at tissues expressing transferrin receptors (such as brain endothelial cells), ensuring that the therapeutic effect is localized to the intended target while minimizing off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-transferrin conjugate achieves enhanced delivery and efficacy by increasing cellular penetration, reducing off-target effects, and prolonging interaction with targets, thereby improving therapeutic outcomes in diseases like Alzheimer's and cancer.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis
Data Source
AI summary
The efficacy and indication of ocrelizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.